Product Description
Mechanisms of Action: 5-HT4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: SK Life Science
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Relenopride](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Irritable Bowel Syndrome|Constipation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
YKP | P2 |
Completed |
Irritable Bowel Syndrome|Constipation |
2014-12-01 |
|
YKP10811C006 | P2 |
Completed |
Constipation |
2014-09-01 |
|
YKP10811C003 | P2 |
Completed |
Constipation |
2013-11-01 |